Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.
about
Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma.Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.Standardized pretreatment inflammatory laboratory markers and calculated ratios in patients with oral squamous cell carcinoma.Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio.Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer.Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.Clinical Value of the Epstein-Barr Virus and p16 Status in Patients with Nasopharyngeal Carcinoma: A Single-Centre Study in Japan.Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis.Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: A meta-analysis.Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer.The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell cancerThe C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.High pretreatment serum gamma-glutamyl transpeptidase predicts an inferior outcome in nasopharyngeal carcinoma.Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis.Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for IPrognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma.Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients.The Lymphocyte-Monocyte Ratio and the Platelet-Lymphocyte Ratio at Diagnosis as Independent Prognostic Factors in Primary Gastrointestinal Diffuse Large B Cell Lymphoma.Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma.Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis.Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study
P2860
Q30235263-76351D1E-3FD2-4907-9205-B534AB35EC6DQ37465628-8B797FD7-0FF9-4BB6-B821-6ED63E99B963Q37702050-DB09A034-8430-4ADA-87C5-DAAB5663F515Q38901921-8AAF457E-B68A-4DA5-9133-EF437B9E2E87Q39062109-C0D13831-239A-4A9E-8330-4BE46CC116EDQ39401725-13B9D209-7EDC-4A4F-84C5-3A6C11D8E530Q40108064-EB710C0A-82E8-457D-B1C5-4E755CF77ACBQ40346047-39BADABF-CDEC-4044-9181-26315210367DQ41035366-33111B89-1509-4269-AAA1-E5C411EB2AA9Q41091179-C3D37F9C-452B-403B-B382-E6066B0CD6F1Q41278675-A2E0ECC7-B321-4ABA-936E-33BAEBAA6DF7Q41694323-D3C2E0D4-7C60-409A-B72A-3C5B8F925411Q42364956-196A88D5-975F-4D7F-AB04-31C31CE02791Q42366562-C7BE4168-69A4-4D7A-B2F2-88F4613B2196Q42371608-1A8477D8-8DEE-42AC-830B-0863C68B4CFCQ42377778-E64C316F-8881-458E-9206-ED0B064BA3FBQ47111490-A35DF8AF-20EC-473C-88FB-6570DA24C610Q47630575-CECEFFD9-5351-42B8-B05D-03E8549684AEQ48212629-D5E1956B-5A05-4722-9F5A-304E4003745EQ54253295-3823090A-4AC7-4B0A-84A9-F0BD84E07D0EQ54967110-CDA88157-A1A2-4D48-8AA4-2C29851A3340Q55279094-3E9E01A9-4418-416E-828E-7FD28C1D2F48Q55340763-CA7D7875-6A51-4C1B-A378-7E2172CE5B37Q57474616-3F8BBB84-A1A7-4A29-B433-7039313E7A6B
P2860
Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.
@en
type
label
Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.
@en
prefLabel
Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.
@en
P2093
P2860
P356
P1433
P1476
Pretreatment hematologic marke ...... and platelet-lymphocyte ratio.
@en
P2093
Dongbo Liu
Guangyuan Hu
Guoqing Hu
Guoxian Long
Linli Zhang
P2860
P304
P356
10.1002/HED.24224
P478
38 Suppl 1
P577
2015-09-11T00:00:00Z